Intuitive Surgical, Inc.
Acquisitions
3
Major Deals Covered
$340M
Disclosed Deal Value
Intuitive Surgical's largest disclosed acquisition here is Schölly Fiberoptic (Robotic Endoscope Business) for $150M in 2023. This page covers 3 major deals from 2003 to 2023, each with its price where disclosed and the reason behind it.
| Company | Year | Price | Purpose |
|---|---|---|---|
| Computer Motion, Inc. | 2003 | $140.0M | Merged with its primary competitor to resolve intellectual property and patent litigation, combining patents for ZEUS and da Vinci systems. |
| Orpheus Medical | 2020 | $50.0M | Acquired to bolster medical imaging integration, OR video documentation, and hospital network data interoperability. |
| Schölly Fiberoptic (Robotic Endoscope Business) | 2023 | $150.0M | Acquired Schölly's robotic endoscope visualization business to secure proprietary optical technology and supply chain control. |
2023
$150M
Acquired Schölly's robotic endoscope visualization business to secure proprietary optical technology and supply chain control.
Secured world-class 3D HD visualization technology and optical manufacturing capabilities in-house.
Strengthened optical supply chain resilience and accelerated next-gen visualization R&D.
2020
$50M
Acquired to bolster medical imaging integration, OR video documentation, and hospital network data interoperability.
Enhanced Intuitive's digital ecosystem, enabling hospitals to archive and analyze surgical video data seamlessly.
Successfully integrated into Intuitive's digital and software services division.
2003
$140M
Merged with its primary competitor to resolve intellectual property and patent litigation, combining patents for ZEUS and da Vinci systems.
Eliminated patent litigation, consolidated market monopoly in surgical robotics, and unified engineering talent.
Highly successful strategic merger that cemented Intuitive's undisputed leadership in the medical robotics industry.
The company's growth strategy centers on expanding the global installed base of da Vinci systems into underpenetrated international markets (particularly Europe and Asia), driving procedure utilization growth across existing hospital accounts, commercializing next-generation platforms like da Vinci 5 and Ion (endoluminal system), and advancing digital and artificial intelligence capabilities in surgery.
Intuitive Surgical operates a high-margin razors-and-blades commercial model. The company places da Vinci surgical systems in hospitals—either through upfront capital sales, long-term leases, or usage-based placement agreements—and secures highly predictable, high-margin recurring revenue streams from single-use EndoWrist instruments, replacement accessories, and annual software and hardware service contracts. Instruments and services consistently account for over 75% of total annual revenues.
Intuitive's most transformative acquisition was its 2003 merger with primary rival Computer Motion, which eliminated patent litigation, consolidated telerobotic patents, and secured market monopoly.
The 2000 acquisition of Orpheus Medical added advanced medical imaging integration, OR video documentation, and hospital network data interoperability to Intuitive's digital ecosystem.
Acquiring Schölly's robotic endoscope business in 2023 brought world-class 3D HD visualization optics and manufacturing capabilities in-house, securing supply chain control.
Intuitive pursues targeted, strategic acquisitions that complement its core robotic platforms, enhance digital surgery capabilities, or secure critical optical and software intellectual property.
Yes, backed by robust operating cash flows and a fortress balance sheet, Intuitive funds strategic acquisitions comfortably out of cash reserves without incurring debt.
Compare corporate acquisition records, deal values, and strategic targets
Explore Intuitive Surgical
Core profile pages, founders and related research hubs for this company.